These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 15819377)

  • 1. Cardiovascular prevention in type 2 diabetic patients: review of efficacious treatments.
    Goderis G; Boland B
    Acta Clin Belg; 2004; 59(6):329-39. PubMed ID: 15819377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
    Dailey G
    Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Type 2 diabetes and cardiovascular risk: lessons from therapeutic trials].
    Lièvre M
    Rev Prat; 2001 Oct; 51(16):1793-9. PubMed ID: 11795124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
    Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
    JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interventions in type 2 diabetes mellitus and cardiovascular mortality-An overview of clinical trials.
    Burggraaf B; Castro Cabezas M
    Eur J Intern Med; 2017 Jul; 42():1-15. PubMed ID: 28554780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ethical considerations in cardiovascular prevention.
    Follath F
    Fundam Clin Pharmacol; 2009 Dec; 23(6):669-73. PubMed ID: 19500153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management.
    Petersen JL; McGuire DK
    Diab Vasc Dis Res; 2005 Feb; 2(1):9-15. PubMed ID: 16305067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?].
    Dussol B; Berland Y
    Nephrol Ther; 2006 May; 2(2):51-74. PubMed ID: 16895717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The results of Look AHEAD do not row against the implementation of lifestyle changes in patients with type 2 diabetes.
    Annuzzi G; Rivellese AA; Bozzetto L; Riccardi G
    Nutr Metab Cardiovasc Dis; 2014 Jan; 24(1):4-9. PubMed ID: 24388434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cardiovascular prevention with peripheral artery disease].
    Vértes A
    Orv Hetil; 2007 Jul; 148(28):1303-9. PubMed ID: 17611180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The HOPE Study (Heart Outcomes Prevention Evaluation).
    Sleight P
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
    Høgh AL
    Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic options for lowering LDL-C in type 2 diabetes: a nurse practitioner's perspective.
    Lew KN; Kent DJ; Muñoz AA; Melkus GD
    J Am Assoc Nurse Pract; 2013 Sep; 25(9):488-94. PubMed ID: 24170653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
    Khan NA; McAlister FA; Lewanczuk RZ; Touyz RM; Padwal R; Rabkin SW; Leiter LA; Lebel M; Herbert C; Schiffrin EL; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; DeChamplain J; Pylypchuk G; Logan AG; Gledhill N; Petrella R; Campbell NR; Arnold M; Moe G; Hill MD; Jones C; Larochelle P; Ogilvie RI; Tobe S; Houlden R; Burgess E; Feldman RD;
    Can J Cardiol; 2005 Jun; 21(8):657-72. PubMed ID: 16003449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.